山东医药2016，Vol.56Issue(24)：63-65,3.DOI:10.3969/j.issn.1002-266X.2016.24.024
表柔比星联合多西他赛新辅助化疗对乳腺癌患者癌组织 Ki-67表达的影响及意义
Effect of neoadjuvant chemotherapy with docetaxel and epirubicin on Ki-67 expression in patients with breast cancer
冯宇 1赵霞 1吕淑贞 1穆颖 1王丹丹 1李艳萍1
作者信息
- 1. 首都医科大学附属北京世纪坛医院，北京100038
- 折叠
摘要
Abstract
Objective To investigate the effect of neoadjuvant chemotherapy with epirubicin and docetaxel on Ki -67 expression in patients with breast cancer and its significance .Methods Eighty-six cases of patients with breast cancer treated with breast cancer radical surgery were selected in this study , epirubicin combined with docetaxel neoadjuvant chemotherapy were carried out before operation .Quantitative PCR and Western blotting were used to detect the expression of Ki-67 mRNA and protein before and after chemotherapy .After 5-year follow-up, we used Kaplan-meire survival curve method to analyze disease-free survival ( DFS) and overall survival ( OS) , used Cox proportional hazard regression model to analyze the relationship between DFS , OS and Ki-67 expression .Results The expression of Ki-67 mRNA and Ki-67 pro-tein in the breast cancer after chemotherapy were lower than that before chemotherapy (all P<0.05).According to Ki-67 mRNA expression changes , patients were further divided into higher change group ( down-regulation of Ki-67 mRNA was more than or equal to 10%, 57 cases) and lower change group (Ki-67 mRNA reduced less than 10%, 39 cases).DFS of the two groups (higher and lower changes group respectively ) was 36, 22 months and OS was 37, 45 months, and there were significant differences between the two groups (all P<0.01).Ki-67 was the an independent influencing factor for DFS and OS in patients with breast cancer (HR were 1.807, 1.768, all P<0.05).Conclusion Epirubicin and docetax-el neoadjuvant chemotherapy can down-regulate the expression of Ki-67 in tumor tissues of patients with breast cancer , and the high expression of Ki-67 is related to the poor prognosis .关键词
乳腺癌/新辅助化疗/表柔比星/多西他赛/Ki-67Key words
breast carcinoma/neoadjuvant chemotherapy/epirubicin/docetaxel/Ki-67分类
医药卫生引用本文复制引用
冯宇,赵霞,吕淑贞,穆颖,王丹丹,李艳萍..表柔比星联合多西他赛新辅助化疗对乳腺癌患者癌组织 Ki-67表达的影响及意义[J].山东医药,2016,56(24):63-65,3.
